Compare PEN & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEN | NCLH |
|---|---|---|
| Founded | 2004 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 10.9B |
| IPO Year | 2015 | 2011 |
| Metric | PEN | NCLH |
|---|---|---|
| Price | $333.28 | $18.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 17 |
| Target Price | ★ $357.33 | $24.82 |
| AVG Volume (30 Days) | 548.7K | ★ 18.6M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1155.56 | N/A |
| EPS | ★ 4.52 | 0.92 |
| Revenue | $1,403,665,000.00 | ★ $5,396,175,000.00 |
| Revenue This Year | $14.34 | $9.96 |
| Revenue Next Year | $13.71 | $6.60 |
| P/E Ratio | $73.42 | ★ $20.61 |
| Revenue Growth | ★ 17.50 | 10.71 |
| 52 Week Low | $221.26 | $15.31 |
| 52 Week High | $362.41 | $27.18 |
| Indicator | PEN | NCLH |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 40.30 |
| Support Level | $326.58 | $17.95 |
| Resistance Level | $336.01 | $24.64 |
| Average True Range (ATR) | 2.27 | 0.96 |
| MACD | 0.43 | -0.06 |
| Stochastic Oscillator | 72.14 | 2.51 |
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.